A missed deadline on benefit-sharing rules leaves the landmark Pandemic Agreement unable to move toward ratification—and global pathogen surveillance vulnerable to the same equity failures that derailed pandemic response in 2020.
A critical deadline for finalizing one of the most consequential components of global pandemic preparedness architecture has been missed, leaving the landmark WHO Pandemic Agreement in a holding pattern and unable to move toward ratification. After an intensive week of late-night sessions in Geneva, WHO member states concluded the resumed sixth meeting of the Intergovernmental Working Group (IGWG) on April 27–May 1, 2026, without reaching agreement on the Pathogen Access and Benefit Sharing (PABS) Annex — the final unresolved piece of the Pandemic Agreement adopted in May 2025.
The IGWG has now extended its negotiating mandate by one year, with the Eightieth World Health Assembly in May 2027 set as the new target for finalizing the PABS Annex. A special session of the World Health Assembly could be convened earlier in 2026 if an agreement is reached sooner. Until the Annex is finalized, the Pandemic Agreement cannot open for signature and ratification — a significant setback for global health security efforts. If a novel pathogen with pandemic potential emerged today, the world would still lack the coordinated, equitable framework needed to ensure rapid and fair distribution of medical countermeasures.
What PABS Is — and Why It Matters
The PABS system is designed to ensure that countries rapidly share pathogen samples and genetic sequence data with pandemic potential, while receiving fair and equitable benefits in return — including access to vaccines, diagnostics, and therapeutics developed from that data. The mechanism is intended to address one of the most visible failures of pandemic response: low- and middle-income countries shared biological samples that helped produce medical countermeasures they were then unable to access at affordable prices or in a timely manner.
The PABS Annex is not a peripheral provision. It is the legal and operational framework without which the broader Pandemic Agreement carries limited force. As WHO Director-General Dr. Tedros Adhanom Ghebreyesus stated at the close of negotiations: “The PABS annex is the last piece of the puzzle not only for the Pandemic Agreement but all initiatives that WHO and Member States have implemented as a result of lessons learned from the COVID-19 pandemic.”
The Benefit-Sharing Stalemate: What’s Actually Being Fought Over
Despite progress on governance provisions, benefit-sharing arrangements, and use of terms, the fundamental architecture of the PABS system remains contested. The central dispute hinges on a single question: should pharmaceutical companies be legally required to share medical products derived from pathogen data, or should benefit-sharing be voluntary?
Negotiating blocs including the Africa Group and the Group for Equity have pushed for mandatory contracts — binding legal obligations ensuring that companies developing vaccines, diagnostics, or therapeutics from shared pathogen data must provide access to those products in developing nations at affordable prices and within defined timelines. Their argument is straightforward: without enforceable mandates, companies have no incentive to prioritize equitable access when profits are at stake.
Several developed nations, led by representatives from European countries, have argued that mandatory requirements could discourage research and investment, potentially slowing the pace of medical innovation during a crisis. They proposed a hybrid model: countries would choose between “open access” (mandatory benefit-sharing with defined compliance checkpoints) and “closed access” (voluntary arrangements negotiated case-by-case), with both options subject to oversight by a WHO-coordinated mechanism.
The hybrid approach was discussed at length during the resumed session, with cross-regional exchanges between the EU and Africa Group running late into Wednesday night. However, the model failed to gain sufficient support from either side. Developing nations viewed it as too permissive — allowing companies to opt out of mandatory obligations undermined the point of having a binding system. Developed nations remained concerned that even the “open access” track imposed sufficient constraints to discourage participation. By Friday, negotiations had pivoted to discussing an extension rather than resolving the impasse.
IGWG Co-Chair Ambassador Tovar da Silva Nunes of Brazil acknowledged the difficulty: “Finalizing a document of such technical and legal complexity requires precision and dedication, both of which the Member States have demonstrated in full. We are not there yet, but with an extension of our negotiations, we will get there.”
Global Health Experts Warn of Continued Vulnerability
The failure to meet the deadline drew sharp responses from senior figures in the global health security community. Former Liberian President Ellen Johnson Sirleaf and former New Zealand Prime Minister Helen Clark — co-chairs of the WHO’s Independent Panel for Pandemic Preparedness and Response — called the outcome “deeply regrettable,” warning that “if a new pathogen emerged today, the world remains largely unprepared for it.”
The Independent Panel, established to review the global response to pandemic threats and recommend reforms, noted that even without a finalized PABS Annex, governments should act now to strengthen implementation of the amended International Health Regulations, update national pandemic preparedness plans, and invest in surveillance systems. The Panel also pointed to a forthcoming UN High-Level Meeting on Pandemic Prevention, Preparedness and Response in New York in September as an opportunity for leaders to demonstrate commitment and address persistent gaps in financing, equity, and coordination.
The Resilience Action Network International (Rani), a civil society organization advocating for equitable pandemic preparedness, expressed disappointment at the outcome and urged member states to pursue a PABS system that delivers substantive change. “An effective, equitable PABS system depends on an acceptable level of guaranteed benefits — and that must be non-negotiable,” the organization stated.
What Comes Next
The IGWG will hold its seventh meeting from July 6–17, 2026. In advance, informal hybrid meetings will be organized focusing on access, benefit-sharing, contracts, and core terms of reference for the WHO Coordinated Laboratory Network and potential WHO PABS-recognized sequence databases. Working modalities, an updated timeline, and deliverables will also be considered, alongside initial discussions on a Coordinating Financial Mechanism.
The extended timeline through May 2027 provides additional negotiating space, but also delays the operationalization of a system that could be critical if emerging infectious disease threats accelerate. Absent agreement on binding benefit-sharing mechanisms, the next pandemic — whether it emerges in 2026 or 2030 — will likely reproduce the same inequities and delays in equitable access that characterized the previous decade. Member states have 13 months to close a gap that has already cost years of negotiation and the credibility of the broader pandemic preparedness architecture.
Sources and further reading:
PABS Deal Deferred – Resilience Action Playbook
WHO Member States agree to extend negotiations on Pathogen Access and Benefit Sharing annex – World Health Organization
The World Cannot Wait to Prepare for New Pandemic Threats – The Independent Panel for Pandemic Preparedness and Response
Final Report – Resumed sixth meeting of the open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – World Health Organization